Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06316973 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants
A Phase 1 study, sponsored by Clear Scientific.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT06316973: Completed Phase 1 study, sponsored by Clear Scientific.
NCT06316973 is a Phase 1 study that has completed, run by Clear Scientific. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06316973, a Phase 1 study, has completed, sponsored by Clear Scientific.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this Phase 1a study is to evaluate safety, tolerability, and pharmacokinetics (PK) of single, ascending doses of CS-1103, administered by intravenous (IV) infusion in healthy participants.
Primary Outcome
Treatment-emergent adverse events assessed through physical examinations, vital signs (blood pressure, pulse rate, respiratory rate, oxygen saturation, and body temperature), electrocardiograms (digital 12-lead electrocardiograms (ECGs). Any correlation between CS-1103 plasma concentrations and changes in QT intervals will be noted), and laboratory parameters (clinical chemistry, hematology, coagulation, and urinalysis).
Interventions
- DRUG Sterile Saline
- DRUG CS-1103
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-02-07 |
| Est. Completion | 2024-06-06 |
| Phase | Phase 1 |
What the finished NCT06316973 record still lists
NCT06316973 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which Sterile Saline is the first listed.
NCT06316973 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06316973 about?
NCT06316973 is a clinical study titled "A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants". The purpose of this Phase 1a study is to evaluate safety, tolerability, and pharmacokinetics (PK) of single, ascending doses of CS-1103, administered by intravenous (IV) infusion in healthy participants.
What is the current status of trial NCT06316973?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2024-02-07. Estimated completion is 2024-06-06.
What interventions are being tested in trial NCT06316973?
The interventions under investigation include: Sterile Saline (DRUG), CS-1103 (DRUG).
Who is sponsoring clinical trial NCT06316973?
This trial is sponsored by Clear Scientific, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06316973's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI